Campus Moncloa
Campus of International Excellence
Cannabinoides
Scientific publications
Year | Total | IF average | Q moda | Internacionalization | Agregation |
2024 | - | - | - | - | - |
2023 | 5 | 5.801 | Q1 | 60% | - |
2022 | 4 | 6.242 | Q1 | 50% | - |
2021 | 13 | 5.047 | Q1 | 30.77% | - |
2020 | 6 | 5.153 | Q1 | 33.33% | - |
2019 | 7 | 4.698 | Q1 | 28.57% | - |
2018 | 7 | 4.778 | Q1 | 42.86% | - |
2017 | 6 | 2.951 | Q1 | 66.67% | - |
2016 | 14 | 4.594 | Q1 | 57.14% | - |
2015 | 11 | 13.307 | Q1 | 45.45% | - |
2014 | 9 | 4.767 | Q1 | 44.44% | - |
2013 | 9 | 3.993 | Q1 | 55.56% | - |
2012 | 6 | 3.46 | Q1 | 66.67% | - |
2011 | 7 | 5.651 | Q1 | 71.43% | - |
2010 | 6 | 4.235 | Q1 | 50% | - |
2009 | 7 | 4.44 | Q1 | 28.57% | - |
Total | 117 | 5.275 | Q1 | 48.76% | - |
Principal categories: | Pharmacology & Pharmacy | Neurosciences | Chemistry, Medicinal |
Scientific publications linked to the cluster
2023
- Thienopyrimidine derivatives as GPR55 receptor antagonists: Insight into structure-activity relationship. Figuerola-Asencio L, Morales P, Zhao P, Hurst D, Sayed S, Colón K, Gómez-Cañas M, Fernández-Ruiz J, Croatt M, Reggio P, Abood M, Jagerovic N. ACS Med Chem Lett. 2022 Dec 2;14(1):18-25; eCollection 2023 Jan 12
Category: Chemistry, Medicinal Quartile: 2º
Impact factor: 4.632 - Retinal tissue shows glial changes in Dravet Symdrome knock-in mouse model. Salazar JJ, Satriano A, Matamoros JA, Fernández-Albarral JA, Salobrar-García E, López-Cuenca I, de Hoz R, Sánchez-Puebla L, Ramírez JM, Alonso C, Satta V, Hernández-Fisac I, Sagredo O, Ramírez AI. Int J Mol Sci. 2023 Feb 1;24(3):2727.
Category: Biochemistry & Molecular Biology Quartile: 1º
Impact factor: 6.208 - Preclinical investigation in FAAH inhibition as a neuroprotective therapy for frontotemporal dementia using TDP-43 transgenic male mice. Santos-García I, Rodríguez-Cueto C, Villegas P, Piscitelli F, Lauritano A, Shen C, di Marzo V, Fernández-Ruiz J, de Lago E. J Neuroinflammation. 2023 May 6;20(1):108
Category: Neurosciences Quartile: 1º
Impact factor: 9.594 - Disease-modifying effects of cannabidiol, β-caryophyllene and their combination in Syn1-Cre/Scn1aWT/A1783V mice, a preclinical model of Dravet síndrome. Alonso C, Satta V, Hernández-Fisac I, Fernández-Ruiz J, Sagredo O. Neuropharmacology. 2023 Jun 6;109602
Category: Pharmacology & Pharmacy Quartile: 1º
Impact factor: 5.273 - The cannabigerol derivative VCE-003.2 exerts therapeutic effects in 6-Hydroxydopamine-lesioned mice: Comparison with the classic dopaminergic replacement therapy. Rodríguez-Carreiro S, Navarro E, Muñoz E, Fernández-Ruiz J. Brain Sci. 2023 Aug 31;13(9):1272
Category: Neurosciences Quartile: 3º
Impact factor: 3.300
2022
- New statement about NRF2 in amyotrophic lateral sclerosis and frontotemporal dementia. Lastres-Becker I, de Lago E, Martínez A, Fernández-Ruiz J. Biomolecules. 2022 Aug 29;12(9):1200
Category: Biochemistry & Molecular Biology Quartile: 2º
Impact factor: 6.064 - Discovery of Mitophagy Inhibitors with Therapeutic Potential in Different Familial Amyotrophic Lateral Sclerosis Mutations. Ines Maestro, Laura R de la Ballina, Gracia Porras, Silvia Corrochano, Eva De Lago, Anne Simonsen, Patricia Boya, Ana Martinez. Int J Mol Sci. 2022 Oct 21;23(20):12676
Category: Biochemistry & Molecular Biology Quartile: 1º
Impact factor: 6.208 - Preclinical investigation of beta-caryophyllene as a therapeutic agent in a experimental murine model of Dravet síndrome. Alonso C, Satta V, Díez P, Fernández-Ruiz J, Sagredo O. Neuropharmacology, 205.108914.
Category: Pharmacology & Pharmacy Quartile: 1º
Impact factor: 5.250 - TDP-43 Modulation by Tau-Tubulin Kinase 1 Inhibitors: A New Avenue for Future Amyotrophic Lateral Sclerosis Therapy. Nozal V, Martinez-Gonzalez L, Gomez-Almeria M, Gonzalo-Consuegra C, Santana P, Chaikuad A. Perez-Cuevas E, Knapp S, Lietha D, Ramirez D, Petralla S, Monti B, Gil C, Martin-Requero A. Palomo V, de Lago E, Martínez A. J Med Chem
. 2022 Jan 27;65(2):1585-1607
Category: Chemistry, Medicinal Quartile: 1º
Impact factor: 7.446
2021
- Neuroprotection with the cannabigerol quinone derivative VCE-003.2 and its analogs CBGA-Q and CBGA-Q-Salt in Parkinson’s disease using 6-hydroxydopamine-lesioned mice. Burgaz S, García MC, Gómez-Cañas M, Navarrete C, García-Martín A, Rolland A, del Río C, Casarejos MJ, Muñoz E, Gonzalo-Consuegra C, Muñoz E, Fernández-Ruiz J. Mol Cell Neurosci. 2021 Jan;110:103583
Category: Neurosciences Quartile: 2º
Impact factor: 3.182 - Targeting nuclear protein TDP-43 by cell division cycle kinase 7 inhibitors: a new therapeutic approach for amyotrophic lateral sclerosis. Rojas-Prats E, Martínez-González L, Gonzalo-Consuegra C, Liachko NF, Pérez C, Ramírez D, Kraemer BC, Martín-Requero A, Pérez DI, Gil C, de Lago E, Martínez A. Eur J Med Chem. 2021 Jan 15;210:112968
Category: Chemistry, Medicinal Quartile: 1º
Impact factor: 5.572 - Analogues of cannabinoids as multitarget drugs in the treatment of Alzheimer´s disease. Sánchez-Montero JM, Agis-Torres A, Solano D, Söllhuber M, Fernández M, Villaro W, Gómez-Cañas M, García-Arencibia M, Fernández-Ruiz J, Egea J, Martín MI, Girón R Eur J Pharmacol
. 2021 Jan 15;895:173875
Category: Pharmacology & Pharmacy Quartile: 2º
Impact factor: 3.263 - Neuropathological characterization of a Dravet sÍndrome knock-in mouse model useful for investigating cannabinoid treatments. Satta V, Alonso C, Díez P, Martín-Suárez S, Rubio M, Encinas JM, Fernández-Ruiz J, Sagredo O. Frontiers in Molecular Neuroscience, 13 602801 (2020)
Category: Neurosciences Quartile: 2º
Impact factor: 4.057 - Targeting the CB2 receptor and other endocannabinoid elements to delay disease progression in amyotrophic lateral sclerosis. Rodríguez-Cueto C, García-Toscano L, Santos-García L, Gómez-Almería M, Gonzalo-Consuegra C, Espejo-Porras F, Fernández-Ruiz J, de Lago E. Br J Pharmacol
. 2021 Mar;178(6):1373-1387. Epub 2021 Feb 20.
Category: Pharmacology & Pharmacy Quartile: 1º
Impact factor: 7.730 - Retinal ganglion cell loss and microglial activation in a SOD1G93A mouse model of amiyotrophic lateral sclesoris. Rojas P, Ramírez AI, Cadena M, Fernández-Albarral JA, Salobrar-García E, López-Cuenca I, Santos-García I, de Lago E, Urcelay-Segura JL, Ramírez JM, de Hoz R, Salazar JJ. International Journal of Molecular Sciences. 2021 Feb 7;22(4):1663.
Category: Biochemistry & Molecular Biology Quartile: 1º
Impact factor: 4.556 - Cannabinoid receptor CB2 ablation protects against TAU induced neurodegeneration. Galán-Ganga, M, Rodríguez-Cueto C, Merchán-Rubira J, Hernández F, Ávila J, Posada-Ayala M, Lanciego JL, Luengo E, López MG, Rábano A, Fernández-Ruiz J, Lastres-Becker I. Acta Neuropathol Commun. 2021 May 17;9(1):90.
Category: Neurosciences Quartile: 1º
Impact factor: 6.270 - (+)-trans-Cannabidiol-2-hydroxy pentyl is a dual CB1R antagonist/CB2R agonist that prevents diabetic nephropathy in mice. González-Mariscal I, Carmona-Hidalgo B, Winkler M, Unciti-Broceta JD, Escamilla A, Gómez-Cañas M, Fernández-Ruiz J, Fiebich BL, Romero-Zerbo SY, Bermúdez-Silva FJ, Collado JA, Muñoz E. Pharmacological Research 169, July 2021, 105492
Category: Pharmacology & Pharmacy Quartile: 1º
Impact factor: 5.893 - Neuroprotection with the cannabidiol quinone derivative VCE-004.8 (EHP-101) against 6-hydroxydopamine in cell and murine models of Parkinson’s disease. Burgaz S, García MC, Gómez-Cañas M, Rolland A, Muñoz E, Fernández-Ruiz J. Molecules . 2021 May 28;26(11):3245.
Category: Biochemistry & Molecular Biology Quartile: 2º
Impact factor: 3.267 - Tideglusib, a non-ATP competitive inhibitor of GSK-3β as a drug candidate for the treatment of Amyotrophic Lateral Sclerosis. Martinez-Gonzalez L, Gonzalo-Consuegra C, Gómez-Almería M, Porras G, de Lago E, Martin-Requero A, Martinez A. Int J Mol Sci. 22(16):8975
Category: Biochemistry & Molecular Biology Quartile: 1º
Impact factor: 5.923 - Inactivation of the CB2 receptor accelerated the neuropathological deterioration in TDP-43 transgenic mice, a model of amyotrophic lateral sclerosis. Rodríguez-Cueto C, Gómez-Almería M, García-Toscano L, Romero J, Hillard CJ, de Lago E, Fernández-Ruiz J. Brain Pathol. 2021 May 13;e12972. Online ahead of print.
Category: Pathology Quartile: 1º
Impact factor: 5.568 - BiP heterozigosity aggravates pathological deterioration in experimental amyotrophic lateral sclerosis: possible relation with CB1 receptor-mediated neuroprotection? Gómez-Almería M, Burgaz S, Costas-Insua C, Rodríguez-Cueto C, Santos-García i, Eodriguez-Crespo i, García MC, Guzmán M, de Lago E, Fernández-Ruiz J. Int J Mol Sci. 2021 Nov 20;22(22):12533
Category: Biochemistry & Molecular Biology Quartile: 1º
Impact factor: 5.923 - Preclinical investigation in neuroprotective effects of the GPR55 ligand VCE-006.1 in experimental models of Parkinson’s disease and amyotrophic lateral sclerosis. Burgaz S, García MC, Gonzalo-Consuegra C, Gómez-Almería M, Ruiz-Pino F, Unciti JD, Gómez-Cañas M, Alcalde J, Morales P, Jagerovic N, Rodríguez-Cueto C, de Lago E, Muñoz E, Fernández-Ruiz J. Molecules
. 2021 Dec 16;26(24):7643
Category: Biochemistry & Molecular Biology Quartile: 2º
Impact factor: 4.411
2020
- Pharmacokinetics of Sativex in dogs: Towards a potential cannabinoid-based therapy for canine disorders. Fernández-Trapero M, Pérez-Díaz C, Espejo-Porras F, de Lago E, Fernández-Ruiz J. Biomolecules. 2020 Feb 11;10(2). pii: E279
Category: Biochemistry & Molecular Biology Quartile: 1º
Impact factor: 4.694 - Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1δ kinase inhibitor treatment. Martínez-González L, Rodríguez-Cueto C, Cabezudo D, Bartolomé F, Andrés-Benito P, Ferrer I, Gil C, Martín-Reguero A, Fernández-Ruiz J, Martínez A, de Lago E. Sci Rep
. 2020 Mar 10;10(1):4449.
Category: Multidisciplinary Sciences Quartile: 1º
Impact factor: 4.011 - Beneficial effects of the phytocannabinoid Delta9-THCV in L-DOPA-induced dyskinesia in Parkinson´s disease. Espadas I, Keifman E, Palomo-Garo C, Burgaz S, García MC, Fernández-Ruiz J, Moratalla R. Neurobiol Dis. 2020 Jul;141:10489
Category: Neurosciences Quartile: 1º
Impact factor: 5.160 - Possible therapeutic applications of cannabis in the neuropsychopharmacology field. Fernández-Ruiz J, Galve-Roperh I, Sagredo O, Guzmán M. Eur Neuropsychopharmacol. 2020 Jul;36:217-234
Category: Clinical Neurology Quartile: 1º
Impact factor: 4.468 - Discovery of homobivalent bitopic ligands of the cannabinoid CB2 receptor. Morales P, Navarro G, Gómez-Autet M, Redondo L, Fernández-Ruiz J, Pérez-Benito L, Cordomi A, Pardo L, Franco R, Jagerovic N. Chemistry a European Journal. 2020 Dec 4;26(68):15839-15842
Category: Chemistry, Organic Quartile: 1º
Impact factor: 4.857 - Δ9-Tetrahydrocannabinolic acid alleviates collagen-induced arthritis: role of PPARγ and CB1 receptors. Palomares B, Garrrido-Rodríguez M, Gonzalo-Consuegra C, Gómez-Cañas M, Saenoon S, Soliva R, Collado J, Fernández-Ruiz J, Morello G, Calzado M, Appendino G, Muñoz E. Br J Pharmacol. 2020 Jun 8;177(17):4034-4054
Category: Pharmacology & Pharmacy Quartile: 1º
Impact factor: 7.730
2019
- Cannabidiol administration prevents hypoxia-ischemia-induced hypomyelination in newborn rats. Ceprián M, Vargas C, García-Toscano L, Penna F, Jiménez-Sánchez L, Achicallende S, Elezgarai I, Grandes P, Hind W, Pazos MR, Martínez-Orgado J. Front Pharmacol. 2019 Sep 26;10:1131. eCollection 2019.
Category: Neurosciences Quartile: 2º
Impact factor: 3.720 - Structure-effect relationships of novel semi-synthetic cannabinoid derivates. Götz MR, Collado JA, Fernández-Ruiz J, Fiebich BL, García-Toscano L, Gómez-Cañas M, Koch O, Leha A, Muñoz E, Navarrete C, Pazos MR, Holgrabe U. Front Pharmacol. 2019 Nov 20;10:1284. eCollection 2019
Category: Pharmacology & Pharmacy Quartile: 1º
Impact factor: 3.845 - The biomedical challenge of neurodegenerative disorders: an opportunity for cannabinoid-based therapies to improve on the poor current therapeutic outcomes. Fernández-Ruiz, J. British Journal of Pharmacology, 176 1370-1383
Category: Pharmacology & Pharmacy Quartile: 1º
Impact factor: 6.810 - Targeting glial CB2 receptors to delay the progression of the pathological phenotype in TDP-43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosis. Espejo-Porras F, García-Toscano L, Rodríguez-Cueto C, Santos-García I, de Lago E, Fernández-Ruiz J. British Journal of Pharmacology 176, 1585-1600
Category: Pharmacology & Pharmacy Quartile: 1º
Impact factor: 6.810 - Endocannabinoid system in spinocerebellar ataxia type-3 and other autosomal-dominant cerebellar ataxias: potential role in pathogenesis and expected relevance as neuroprotective targets. Gómez-Ruiz M, Rodríguez-Cueto C, Luna-Piñel E, Hernández ML, Fernández-Ruiz J. Front Mol Neurosci. 2019 Apr 24;12:94
Category: Neurosciences Quartile: 2º
Impact factor: 3.902 - Morphine self-administration, Lewis rats, mTOR pathway, extinction, protein synthesis. Ucha M, Coria S, Núñez-Carranza A, Santos-Toscano R, Roura-Martínez D, Fernández-Ruiz J, Higuera-Matas A, Ambrosio E. J Psychopharmacol. 2019 Jul;33(7):882-893. doi: 10.1177/0269881119836206. Epub 2019 Mar 19.
Category: Clinical Neurology Quartile: 1º
Impact factor: 4.738 - Development of an oral treatment with the PPAR--acting cannabinoid VCE-003.2 against the inflammation-driven neuronal deterioration in experimental Parkinson´s disease. Burgaz S, García MC, Gómez-Cañas M, Muñoz E, Fernández-Ruiz J. Molecules. 2019 Jul 25;24(15). pii: E2702.
Category: Biochemistry & Molecular Biology Quartile: 2º
Impact factor: 3.060
2018
- Novel sulfenamides and sulfonamides based on pyridazinone and pyridazine scaffolds as CB1 receptor ligand antagonists. Murineddu G, Deligia F, Ragusa G, García-Toscano L, Gómez-Cañas M, Asproni B, Satta V, Cichero E, Pazos MR, Fossa P, Loriga G, Fernández-Ruiz J, Pinna GA. Bioorg Med Chem. 2018 Jan 1;26(1):295-307
Category: Chemistry, Organic Quartile: 2º
Impact factor: 2.930 - Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson’s disease: possible involvement of different binding sites at the PPARγ receptor. García MC, Gómez-Cañas M, Burgaz S, Palomares B, Gómez-Gálvez Y, Palomo C, Campo S, Ferrer-Hernández J, Pavicic C, Navarrete C, Bellido ML, García-Arencibia M, Pazos MR, Muñoz E, Fernández-Ruiz J. J Neuroinflammation. 2018 Jan 16;15(1):19.
Category: Neurosciences Quartile: 1º
Impact factor: 7.946 - Analysis of endocannabinoid receptors and enzymes in the post-mortem motor cortex and spinal cord of amyotrophic lateral sclerosis patients. Espejo-Porras F, Fernández-Ruiz J, de Lago E. Amyotroph Lateral Scler Frontotemporal Degener. 2018 Jan 19:377-386.
Category: Clinical Neurology Quartile: 2º
Impact factor: 3.054 - VCE-004.3, a cannabidiol aminoquinone derivative, prevents bleomycin-induced skin fibrosis and inflammation trough PPAR-and CB2-dependent pathways. Del Río C, Cantarero I, Palomares B, Gómez-Cañas M, Fernández-Ruiz J, Pavicic C, García-Martín A, Bellido ML, Ortega R, Pérez-Sánchez C, López-Pedrera C, Appendino G, Calzado M, Muñoz E. Br J Pharmacol. 2018 Oct;175(19):3813-3831
Category: Pharmacology & Pharmacy Quartile: 1º
Impact factor: 6.810 - Neuroprotective effects of the cannabigerol quinone derivative VCE-003.2 in SOD1G93A transgenic mice, an experimental model of amyotrophic lateral sclerosis. Rodríguez-Cueto C, Santos-García I, García-Toscano L, Espejo-Porras F, Bellido ML Fernández-Ruiz J, Muñoz E, de Lago E. Biochem Pharmacol. 2018 Nov;157:217-226
Category: Pharmacology & Pharmacy Quartile: 1º
Impact factor: 4.235 - Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system. Aymerich MS, Aso E, Abellanas MA, Tolon RM, Ramos JA, Ferrer I, Romero J, Fernández-Ruiz J. Biochem Pharmacol. 2018 Nov;157:67-84.
Category: Pharmacology & Pharmacy Quartile: 1º
Impact factor: 4.235 - Cannabinoid signalling in the immature brain: Encephalopathies and neurodevelopmental disorders. Sagredo O, Palazuelos J, Gutierrez-Rodriguez A, Satta V, Galve-Roperh I, Martínez-Orgado J. Biochem Pharmacol. 2018 Nov;157:85-96
Category: Pharmacology & Pharmacy Quartile: 1º
Impact factor: 4.235
2017
- Synthesis of a novel CB2 cannabinoid-porphyrin conjugate based on an antitumor chromenopyrazoledione. Morales P, Moreno L, Fernández-Ruiz J, Jagerovic N. J. Porphyrins Phthalocyanines 2017; 21: 67–76
Category: Chemistry, Multidisciplinary Quartile: 3º
Impact factor: 1.087 - Effects of a Sativex-like combination of phytocannabinoids on disease progression in R6/2 mice, an experimental model of Huntington’s disease. Valdeolivas S, Sagredo O, Delgado M, Pozo MA, Fernández-Ruiz Int J Mol Sci. 2017 Mar 23;18(4). pii: E684
Category: Biochemistry & Molecular Biology Quartile: 2º
Impact factor: 3.257 - Altered striatal endocannabinoid signalling in a transgenic mouse model of spinocerebellar ataxia type-3. Rodríguez-Cueto C, Hernández ML, Hillard C, Maciel P, Valdeolivas S, Ramos JA, Gómez-Ruiz M, Fernández-Ruiz J. PLoS One. 2017 Apr 27;12(4):e0176521.
Category: Multidisciplinary Sciences Quartile: 1º
Impact factor: 3.057 - Up-regulation of CB2 receptors in reactive astrocytes in canine degenerative myelopathy, a disease model of amyotrophic lateral sclerosis. Fernández-Trapero M, Espejo-Porras F, Rodríguez-Cueto C, Coates J, Pérez-Diaz C, de Lago E, Fernández-Ruiz J. Dis Model Mech. 2017 May 1;10(5):551-558.
Category: Pathology Quartile: 1º
Impact factor: 4.316 - Modeling neurodegenerative disorders for developing cannabinoid-based neuroprotective therapies. Fernández-Ruiz J, Gómez-Ruiz M, García MC, Hernández M, Ramos JA. Methods Enzymol. 2017;593:175-198
Category: Biochemical Research Methods Quartile: 3º
Impact factor: 2.088 - New pyridazinone-4-carboxamides as new cannabinoid receptor type-2 inverse agonists: Synthesis, pharmacological data and molecular docking. Ragusa G, Gómez-Cañas M, Morales P, Rodríguez-Cueto C, Pazos MR, Asproni B, Cichero E, Fossa P, Pinna GA, Jagerovic N, Fernández-Ruiz J, Murineddu G. Eur J Med Chem. 2017 Jan 4;127:398-412.
Category: Chemistry, Medicinal Quartile: 1º
Impact factor: 3.902
2016
- Deiana V, Gómez-Cañas M, Pazos MR, Fernández-Ruiz J, Asproni B, Cichero E, Fossa P, Muñoz E, Deligia F, Murineddu G, García-Arencibia M, Pinna GA. Tricyclic pyrazoles. Part 8. Synthesis, biological evaluation and modelling of tricyclic pyrazole carboxamides as potential CB2 receptor ligands with antagonist/inverse agonist properties. Eur J Med Chem. 2016 Feb 6;112:66-80
Category: Chemistry, Medicinal Quartile: 1º
Impact factor: 5.447 - Del Río C, Navarrete C, Collado JA, Bellido M, Gomez-Cañas M, Pazos MR, Fernandez-Ruiz J, Pollastro F, Appendino G, Calzado MA, Cantarero I, Muñoz E. The cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor-γ and CB2 pathways. Sci Rep. 2016 Feb 18;6:21703
Category: Multidisciplinary Sciences Quartile: 1º
Impact factor: 5.578 - Morales P, Whyte L, Chicharro R, Gómez-Cañas M, Pazos MR, Goya P, Irving AJ, Fernández-Ruiz J, Ross RA, Jagerovic N. Identification of novel GPR55 modulators using cell-impedance-based label-free technology. Journal of Medicinal Chemitry, 2016 Mar 10;59(5):1840-53
Category: Chemistry, Medicinal Quartile: 1º
Impact factor: 5.447 - García MC, Palomo-Garo C, Gómez-Gálvez Y, Fernández-Ruiz J. Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia. Br J Pharmacol. 2016 Jul;173(13):2069-79.
Category: Pharmacology & Pharmacy Quartile: 1º
Impact factor: 4.990 - Díaz-Alonso J, Paraiso-Luna J, Navarrete C, Del Río C, Cantarero I, Palomares B, Aguareles J, Fernández-Ruiz J, Bellido ML, Pollastro F, Appendino G, Calzado MA, Galve-Roperh I, Muñóz E. VCE-003.2, a novel cannabigerol derivate, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington´s disease. Sci Rep. 2016 Jul 19;6:29789.
Category: Multidisciplinary Sciences Quartile: 1º
Impact factor: 5.228 - Gómez-Cañas M, Morales P, García-Toscano L, Navarrete C, Muñoz E, Jagerovic N, Fernández-Ruiz J, García-Arencibia M, Pazos MR. Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile. Pharmacol Res. 2016 Aug;110:205-15
Category: Pharmacology & Pharmacy Quartile: 1º
Impact factor: 4.408 - Palomo-Garo C, Gómez-Gálvez Y, García MC, Fernández-Ruiz J. Targeting the cannabinoid CB2 receptor to attenuate the progression of motor deficits in LRRK2-transgenic mice. Pharmacol Res. 2016 Aug;110:181-92
Category: Pharmacology & Pharmacy Quartile: 1º
Impact factor: 4.408 - López-Sendón JL, García-Caldentey J, Trigo-Cubillo P, Ruiz-Romero C, García-Ribas G, Alonso-Arias A, García de Yébenes MJ, Tolón RM, Galve-Roperh I, Sagredo O, Valdeolivas S, Resel E, Ortega-Gutiérrez S, García-Bermejo ML, Fernández-Ruiz J, Guzmán M, García de Yébenes Prous J. A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington´s disease. J Neurol. 2016 Jul;263(7):1390-400
Category: Clinical Neurology Quartile: 2º
Impact factor: 3.377 - Morales P, Gómez-Cañas M, Navarro G, Hurst DP, Carrillo-Salinas FJ, Lagartera L, Pazos MR, Goya P, Reggio PH, Guaza C, Franco R, Fernández-Ruiz J, Nagerovic N. Chromenopyrazole, a versatile cannabinoid scaffold with in vivo activity in a model of multiple sclerosis. J Med Chem. 2016 Jul 28;59(14):6753-71. Mención honorífica. Premios Investigación Fundación Dr. Antonio Esteve.
Category: Chemistry, Medicinal Quartile: 1º
Impact factor: 5.589 - Navarro G, Morales P, Rodríguez-Cueto C, Fernández-Ruiz J, Jagerovic N, Franco R. Targeting cannabinoid CB2 receptors in the Central Nervous System. Medicinal chemistry approaches with focus on neurodegenerative disorders. Front Neurosci. 2016 Sep 13;10:406
Category: Neurosciences Quartile: 2º
Impact factor: 3.398 - Rodríguez-Cueto C, Hernández ML, Hillard C, Maciel P, García-García L, Valdeolivas S, Pozo MA, Ramos JA, Gómez-Ruiz M, Fernández-Ruiz J. Dysregulation of the endocannabinoid signaling system in the cerebellum and brainstem in a transgenic mouse model of spinocerebellar ataxia type-3. .Neuroscience. 2016 Dec 17;339:191-209
Category: Neurosciences Quartile: 2º
Impact factor: 3.231 - Rubio M, Valdeolivas S, Piscitelli F, Verde R, Satta V, Barroso E, Montolio M, Aras LM, Di Marzo V, Sagredo O, Fernández-Ruiz J. Analysis of endocannabinoid signaling elements and related proteins in lymphocytes of patients with Dravet syndrome. Pharmacology Research & Perspectives 4, e00220 (2016)
Journal not indexed. - Hernández-Folgado L, Stevenson L, Morales P, Gómez-Cañas M, Pazos MR, Cascio MG, Jagerovic N, Elguero J, Pertwee R, Goya P. Exploring the benzimidazole ring as a substitution for indole in cannabinoid allosteric modulators. Cannabis and Cannabinoid Research 1, 196-201 (2016)
Journal not indexed. - Gómez-Gálvez Y, Palomo-Garo C, Fernández-Ruiz J, García MC. Potential of the cannabinoid CB2 receptor as a pharmacological target against inflammation in Parkinson´s disease. Prog Neuropsychopharmacol Biol Psychiatry. 2016 Jan 4;64:200-8
Category: Clinical Neurology Quartile: 1º
Impact factor: 4.025
2015
- Erdozain A, Rubio M, Valdizán EM, Pazos A, Meana JJ, Fernández-Ruiz J, Alexander S, Callado LF. The endocannabinoid system is altered in the postmortem prefrontal cortex of alcoholic subjects., Addiction Biology, 2015 Jul;20(4):773-83
Category: Substance Abuse Quartile: 1º
Impact factor: 5.914 - Erdozain A, Rubio M, Fernández-Ruiz J, Meana JJ, Callado LF. Altered CB1 receptor coupling to G-proteins in the postmortem caudate nucleus adn cerebellum of alcoholic subjects. Journal of Psychopharmacology 2015 Nov;29(11):1137-45.
Category: Pharmacology & Pharmacy Quartile: 1º
Impact factor: 3.898 - Ragusa G, Gómez-Cañas M, Morales P, Hurst DP, Deligia F, Pazos MR, Pinna GA, Fernández-Ruiz J, Goya P, Reggio PH, Jagerovic N, García-Arencibia M, Murineddu G. Synthesis, pharmacological evaluation and docking studies of pyrrole structure-based CB2 receptor antagonists. European Journal of Medicinal Chemistry 2015 Jul 15;101:651-667
Category: Chemistry, Medicinal Quartile: 1º
Impact factor: 3.432 - Moreno-Martet M, Feliú A, Espejo-Porras F, Mecha M, Carrillo-Salinas FJ, Fernández-Ruiz J, Guaza C, de Lago E. The disease-modifying effects of a Sativex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to delta-9-tetrahydrocannabinol acting through CB1 receptors. Multiple Sclerosis and Related Disorders 2015 Nov;4(6):505-11
Category: Clinical Neurology Quartile: 4º
Impact factor: 0.884 - Adán de Salas-Quiroga, Javier Díaz-Alonso, Daniel García-Rincón, Floortje Remmers, David Vega, María Gómez-Cañas, Beat Lutz, Manuel Guzmán e Ismael Galve-Roperh. Prenatal exposure to cannabinoids evokes long-lasting functional alterations by targeting CB1 receptors on developing cortical neurons. Proc Natl Acad Sci U S A. 2015 Nov 3;112(44):13693-8
Category: Multidisciplinary Sciences Quartile: 1º
Impact factor: 9.674 - Morales P, Blasco-Benito S, Andradas C, Gómez-Cañas M, Flores J, Goya P, Fernández-Ruiz J, Sánchez C, Jagerovic N. Selective, nontoxic CB2 cannabinoid o-quinone with in vivo activity against triple negative breast cáncer. J Med Chem. 2015 Mar 12;58(5):2256-64.
Category: Chemistry, Medicinal Quartile: 1º
Impact factor: 5.480 - Valdeolivas S, Navarrete C, Cantarero I, Bellido ML, Muñoz E, Sagredo O. Neuroprotective properties of cannabigerol in Huntington´s disease. Neurotherapeutics. 2015 Jan;12(1):185-99
Category: Clinical Neurology Quartile: 1º
Impact factor: 3.883 - García MC, Cinquina V, Palomo-Garo C, Rábano A, Fernández-Ruiz J. Identification of CB2 receptors in human nigral neurons that degenerate in Parkinson´s disease. Neurosci Lett. 2015 Feb 5;587:1-4
Category: Neurosciences Quartile: 3º
Impact factor: 99.999 - Espejo-Porras F, Piscitelli F, Verde R, Ramos JA, di Marzo V, de Lago E, Fernández-Ruiz J. Changes in the endocannabinoid signaling sytem in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TPP-43-related disorders. Journal of Neuroimmune Pharmacology 10(2), 233-244 (2015)
Category: Pharmacology & Pharmacy Quartile: 2º
Impact factor: 3.172 - Feliú A, Moreno-Martet M, Mecha M, Carrillo-Salinas FJ, de Lago E, Fernández-Ruiz J, Guaza C. A Sativex-like combination of phytocannabinoids as disease-modifiying therapy in a viral model of multiple sclerosis. British Journal of Pharmacology 2015 Jul;172(14):3579-95
Category: Pharmacology & Pharmacy Quartile: 1º
Impact factor: 4.990 - Fernández-Ruiz J, Moro MA, Martínez-Orgado J. Cannabinoids in neurodegenerative disorders and stroke/brain trauma: from preclinical models to clinical applications. Neurotherapeutics 12, 793-806 (2015)
Category: Clinical Neurology Quartile: 1º
Impact factor: 5.054
2014
- Rodríguez-Cueto C, Benito C, Fernández-Ruiz J, Romero J, Hernández ML, Gómez-Ruiz M. Changes in CB1 and CB2 receptors in the postmortem cerebellum of humans affected by spinocerebellar ataxias. British Journal of Pharmacology 171, 1472-1489 (2014)
Category: Pharmacology & Pharmacy Quartile: 1º
Impact factor: 5.067 - Fernández-Fernández C, Callado LF, Girón R, Sánchez E, Erdozain AM, López-Moreno JA, Morales P, Rodríguez de Fonseca F, Fernández-Ruiz J, Goya P, Meana JJ, Martín MI, Jagerovic N. Combining rimonabant and fentanyl in a single entity: preparation and pharmacological results. Drug Design, Development & Therapy 8, 263-277 (2014)
Category: Chemistry, Medicinal Quartile: 1º
Impact factor: 3.486 - González-Naranjo P, Pérez N, Campillo NE, Pérez C, Arán VJ, Girón R, Sánchez E, Martín MI, Gómez-Cañas M, García-Arencibia M, Fernández-Ruiz J, Páez JA. Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer´s disease.European Journal of Medicinal Chemistry 2014;73:56-72.(2014)
Category: Chemistry, Medicinal Quartile: 1º
Impact factor: 3.499 - Endocannabinoid hydrolyzing enzymes in the postmortem cerebellum of humans affected by hereditary autosomal dominat ataxias. Rodríguez-Cueto C, Benito C, Romero J, Hernández ML, Gómez-Ruiz M, Fernández-Ruiz J. Pathobiology;81:149-159 (2014)
Category: Pathology Quartile: 3º
Impact factor: 1.948 - Ooms M, Rietjens R, Rangarajan J, Vunckx K, Valdeolivas S, Maes F, Himmelreich U, Fernández-Ruiz J, Bormans G, Van Laere K, Casteels C. Early decrease of type 1 cannabinoid receptor binding and phosphodiesterase 10A activity in vivo in R6/2 Huntington mice. Neurobiology of Aging 35, 2858-2869 (2014)
Category: Geriatrics & Gerontology Quartile: 1º
Impact factor: 6.166 - Devinsky O, Cilio MR, Cross H, Fernandez-Ruiz J, French J, Hill C, Katz R, DiMarzo V, Jutras-Aswad D, Notcutt W, Martinez-Orgado J, Robson P, Rohrback B, Thiele E, Whalley B, Friedman D. Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia 2014 Jun;55(6):791-802.
Category: Clinical Neurology Quartile: 1º
Impact factor: 3.909 - Chiarlone A, Bellocchio L, Blázquez C, Resel E, Soria-Gómez E, Cannich A, Ferrero JJ, Sagredo O, Benito C, Romero J, Sánchez-Prieto J, Lutz B, Fernández-Ruiz J, Galve-Roperh I, Guzmán M. A restricted population of CB1 cannabinoid receptors with neuroprotective activity. Proccedings of the National Academy of Sciences of the United States of America 2014 Jun 3;111(22):8257-62
Category: Multidisciplinary Sciences Quartile: 1º
Impact factor: 9.737 - Moreno-Martet M, Espejo-Porras F, Fernández-Ruiz J, de Lago E. Changes in endocannabinoid receptors and enzymes in the spinal cord of SOD1G93A transgenic mice and evaluation of a Sativex®-like combination of phytocannabinoids: interest for future therapies in amyotrophic lateral sclerosis. CNS Neuroscience & Therapeutics 20, 809-815 (2014)
Category: Neurosciences Quartile: 1º
Impact factor: 4.443 - Moreno E, Andradas C, Medrano M, Caffarel MM, Pérez-Gómez E, Blasco-Benito S, Gómez-Cañas M, Pazos MR, Irving AJ, Lluís C, Canela EI, Fernández-Ruiz J, Guzmán M, McCormick PJ, Sánchez C. Targeting CB2-GPR55 receptor heteromers modulates cancer cell signaling. Journal of Biological Chemistry 289, 21960-21972 (2014)
Category: Biochemistry & Molecular Biology Quartile: 1º
Impact factor: 4.651
2013
- Alvarado M, Decara J, Luque MJ, Hernández-Folgado L, Gómez-Cañas M, Gómez-Ruiz M, Fernández-Ruiz J, Elguero J, Jagerovic N, Serrano A, Goya P, Rodríguez de Fonseca F. Novel antiobesity agents: synthesis and pharmacological evaluation of analogues of Rimonabant and LH21. Bioorganic Medicinal Chemistry 21, 1708-1716 (2013)
Category: Chemistry, Organic Quartile: 2º
Impact factor: 2.903 - Fernández-Fernández C, Decara J, Bermúdez-Silva FJ, Sánchez E, Morales P, Gómez-Cañas M, Gómez-Ruiz M, Callado LF, Goya P, Rodríguez de Fonseca F, Martín MI, Fernández-Ruiz J, Meana JJ, Jagerovic N. Description of a bivalent cannabinoid ligand with hypophagic properties. Arch Pharm (Weinheim). 2013 Mar;346(3):171-9
Category: Chemistry, Multidisciplinary Quartile: 2º
Impact factor: 1.540 - Valdeolivas S, Pazos MR, Bisogno T, Piscitelli F, Iannotti F, Allara M, Sagredo O, di Marzo V, Fernández-Ruiz J. The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: potential role of ciclooxygenase-2-dependent metabolism of 2-AG. Celll Death & Disease 4, e862
Category: Cell Biology Quartile: 1º
Impact factor: 6.044 - Morales P, Vara D, Goméz-Cañas M, Zúñiga MC, Olea-Azar C, Goya P, Fernández-Ruiz J, Díaz-Laviada I, Jagerovic N. Synthetic cannabinoid quinones: preparation, in vitro antiproliferative effects and in vivo prostate antitumor activity. European Journal of Medicinal Chemistry 70C, 111-119 (2013)
Category: Chemistry, Medicinal Quartile: 1º
Impact factor: 3.499 - Espejo-Porras F, Fernández-Ruiz J, Pertwee RG, Mechoulam R, García MC. Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors. Neuropharmacology. 2013 Aug 4;75C:155-163
Category: Pharmacology & Pharmacy Quartile: 1º
Impact factor: 4.114 - Casarejos MJ, Perucho J, Gómez A, Muñoz MP, Fernández-Estévez M, Sagredo O, Fernández-Ruiz J, Guzmán M, García de Yébenes J, Mena MA. Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy. J Alzheimers Dis. 2013 Jan 1;35(3):525-39
Category: Neurosciences Quartile: 2º
Impact factor: 4.174 - Fernández-Ruiz J, Sagredo O, Pazos MR, García C, Pertwee RG, Mechoulam R, Martínez-Orgado J. Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? Br J Clin Pharmacol. 2013 Feb;75(2):323-33
Category: Pharmacology & Pharmacy Quartile: 1º
Impact factor: 3.578 - Pryce G, Cabranes A, Fernández-Ruiz J, Bisogno T, Di Marzo V, Long L, Cravatt B, Giovannoni G, Baker D. Control of experimental spasticity by targeting the degradation of endocannabinoids using selective fatty acid amide hydrolase inhibitors. Mult Scler. 19, 1896-1904
Category: Clinical Neurology Quartile: 1º
Impact factor: 4.472 - Valhondo M, Marco I, Martín-Fontecha M, Vázquez-Villa H, Ramos JA, Berkels R, Lauterbach T, Benhamú B, López-Rodríguez ML. New Serotonin 5-HT1A Receptor Agonists Endowed with Antinociceptive Activity in Vivo. Journal of Medicinal Chemistry, 2013 Oct 24;56(20):7851-61
Category: Chemistry, Medicinal Quartile: 1º
Impact factor: 5.614
2012
- Moreno-Martet M, Mestre L, Loría F, Guaza C, Fernández-Ruiz J, de Lago E. Identification of receptors and enzymes for endocannabinoids in NSC-34 cells: Relevance for in vitro studies with cannabinoids in motor neuron diseases. Neuroscience Letters 508, 67-72 (2012)
Category: Neurosciences Quartile: 3º
Impact factor: 2.026 - de Lago E, Moreno-Martet M, Cabranes A, Ramos JA, Fernández- Ruiz J. Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects. Neuropharmacology 62, 2299-2308 (2012)
Category: Pharmacology & Pharmacy Quartile: 1º
Impact factor: 4.114 - Cumella J, Hernández-Folgado L, Girón R, Sánchez E, Morales P, Hurst DP, Gómez-Cañas M, Gómez-Ruiz M, Pinto DCG, Goya P, Reggio P, Martín MI, Fernández-Ruiz J, Silva AMS, Jagerovic N. Chromenopyrazoles: non-psychoactive and selective CB1 cannabinoid agonists with peripheral antinociceptive properties. ChemMedChem 7, 452-463 (2012)
Category: Chemistry, Medicinal Quartile: 2º
Impact factor: 2.835 - González-Granja A, Carrillo Salinas F, Pagani A, Gómez-Cañas M, Negui R, Navarrete C, Mecha M, Mestre L, Fiebich BL, Calzado MA, Bellido ML, Fernández-Ruiz J, Appendino G, Guaza C, Muñoz E. A cannabigerol quinone alleviates neuroinflammation in a chronic model of multiple sclerosis. Journal of Neuroimmune Pharmacology 7, 1002-1016 (2012)
Category: Pharmacology & Pharmacy Quartile: 1º
Impact factor: 3.802 - Pazos MR, Cinquina V, Gómez A, Layunta R, Santos M, Fernández-Ruiz J, Martínez-Orgado J. Cannabidiol administration after hypoxia-ischemia to newborn rats reduces long-term brain injury and restores neurobehavioral function. Neuropharmacology 63, 776-783 (2012)
Category: Pharmacology & Pharmacy Quartile: 1º
Impact factor: 4.114 - Valdeolivas S, Satta V, Pertwee RG, Fernández-Ruiz J, Sagredo O. Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington´s disease: Role of CB1 and CB2 receptors. ACS Chem Neurosci. 2012 May 16;3(5):400-6
Category: Chemistry, Medicinal Quartile: 1º
Impact factor: 3.871
2011
- Jazwa A, Rojo AI, Innamorato NG, Hesse M, Fernández-Ruiz J, Cuadrado A. Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental Parkinsonism. Antioxidants & Redox Signaling 14, 2347-2360 (2011).
Category: Endocrinology & Metabolism Quartile: 1º
Impact factor: 7.189 - Blazquez C, Chiarlone A, Sagredo O, Aguado T, Pazos MR, Resel E, Palazuelos J, Julien B, Salazar M, Borner C, Benito C, Carrasco C, Diez-Zaera M, Paoletti P, Díaz-Hernández M, Ruiz C, Sendtner M, Lucas JJ, García de Yébenes J, Marsicano G, Monory K, Lutz B, Romero J, Alberch J, Ginés S, Kraus J, Fernández-Ruiz J, Galve-Roperh I, Guzmán M. Loss of striatal cannabinoid receptors is a key pathogenic factor in Huntington´s disease. Brain 134, 119-136 (2011).
Category: Neurosciences Quartile: 1º
Impact factor: 9.915 - Marco I, Valhondo M, Martín-Fontecha M, Vázquez-Villa H, Del Río J, Planas A, Sagredo O, Ramos JA, Torrecillas IR, Pardo L, Frechilla D, Benhamú B, López-Rodríguez ML. New serotonin 5-HT(1A) receptor agonists with neuroprotective effect against ischemic cell damage.J Med Chem. 2011 Dec 8;54(23):7986-99.
Category: Chemistry, Medicinal Quartile: 1º
Impact factor: 5.614 - García C, Palomo-Garo C, García-Arencibia M, Ramos JA, Pertwee R, Fernández-Ruiz J. Symptom-relieving and neuroprotective effects of the phytocannabinoid D9-THCV in animal models of Parkinson´s disease. British Journal of Pharmacology 163, 1495-1506 (2011).
Category: Pharmacology & Pharmacy Quartile: 1º
Impact factor: 5.067 - Sagredo O, Pazos MR, Satta V, Ramos JA, Pertwee RG, Fernández-Ruiz J.Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease. Journal of Neurosciences Research 89, 1509-1518 (2011).
Category: Neurosciences Quartile: 2º
Impact factor: 2.974 - Rubio M, Villain H, Docagne F, Benoit DR, Ramos JA, Vivien D, Fernández-Ruiz J, Ali C. Pharmacological activation/inhibition of the cannabinoid system affects alcohol withdrawal-induced neuronal hypersensitivity to excitotoxic insults. Plos One 6, e23690 (2011)
Category: Multidisciplinary Sciences Quartile: 1º
Impact factor: 3.730 - Fernández-Ruiz J, Moreno-Martet M, Rodríguez-Cueto C, Palomo-Garo C, Gómez-Cañas M, Valdeolivas S, Guaza C, Romero J, Guzmán M, Mechoulam R, Ramos JA. Prospects for cannabinoid therapies in basal ganglia disorders. British Journal of Pharmacology 163, 1365-1378 (2011)
Category: Pharmacology & Pharmacy Quartile: 1º
Impact factor: 5.067
2010
- Fernández-Ruiz, J, Hernandez ML, Ramos JA. Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders. CNS Neuroscience & Therapeutics 16, 72-91 (2010).
Category: Pharmacology & Pharmacy Quartile: 1º
Impact factor: 4.443 - Fernández-Ruiz J, García C, Sagredo O, Gómez M, de Lago E. The endocannabinoid system as a target for the treatment of neuronal damage. Expert Opinion on Therapeutic Targets 14, 387-404 (2010).
Category: Pharmacology & Pharmacy Quartile: 1º
Impact factor: 4.130 - Kurz A, Double KL, Lastres-Becker I, Tozzi A, Tantucci M, Bockhart V, Bonin M, García-Arencibia M, Nuber S, Schlaudraff F, Liss B, Fernández-Ruiz J, Gerlach M, Wüllner U, Lüddens H, Calabresi P, Auburger G, Gispert S. A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice.. PLoS One 5, e11464 (2010).
Category: Multidisciplinary Sciences Quartile: 1º
Impact factor: 3.730 - Innamorato NG, Jazwa A, Rojo AI, García C, Fernández-Ruiz J, Grochot-Przeczek, A, Stachurska A, Jozkowicz A, Dulak J, Cuadrado A. Different susceptibility to the Parkinson's toxin MPTP in mice lacking the redox master regulator Nrf2 or its target gene heme oxygenase-1. PLoS One 5, e11838 (2010).
Category: Multidisciplinary Sciences Quartile: 1º
Impact factor: 3.730 - Castillo A, Tolón MR, Fernández-Ruiz J, Romero J, Martinez-Orgado J. The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB2 and adenosine receptors. Neurobiology of Disease 37, 434-440 (2010).
Category: Neurosciences Quartile: 1º
Impact factor: 5.624 - Sagar D, Jhaveri M, Richardson D, Gray R, de Lago E, Fernández-Ruiz J, Barrett D, Kendall D, Chapman V. Endocannabinoid regulation of spinal nociceptive processing in a model of neuropathic pain. European Journal of Neuroscience 31, 1414-1422 (2010).
Category: Neurosciences Quartile: 2º
Impact factor: 3.753
2009
- Fernández-Ruiz J. The endocannabinoid system as a target for treatment of motor dysfunction. British Journal of Pharmacology 156, 1029-1040 (2009)
Category: Pharmacology & Pharmacy Quartile: 1º
Impact factor: 5.067 - Arias F, Ampuero I, Sagredo O, Almodovar F, Sánchez S, Gorgojo JJ, Ramos JA. Lack of association between polymorphisms in cannabinoid receptor gene (CNR1) and fatty acid amide hydroxylase gene (FAAH) and eating disorders in a preliminary study. Psychiatr Genet. 2009 Dec;19(6):336.
Category: Genetics & Heredity Quartile: 3º
Impact factor: 2.365 - Rubio M, de Miguel R, Fernández-Ruiz J, Gutiérrez-López D, Carai MA, Ramos JA. Effects of a short-term exposure to alcohol in rats on FAAH enzyme and CB1 receptor in different brain areas. Drug and Alcohol Dependence 99 : 354-358 (2009).
Category: Substance Abuse Quartile: 2º
Impact factor: 3.141 - Gispert S, Ricciardi F, Kurz A, Azizov M, Hoepken H, Becker D, Voos W, Leuner K, Müller W, Kudin A, Kunz W, Zimmermann A, Roeper J, Wenzel D, Jendrach M, García-Arencíbia M, Fernández-Ruiz J, Huber L, Rohrer H, Barrera M, Reichert A, Rüb U, Chen A, Nussbaum R, Auburger G. Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration. PLOS One 4, e 5777 (2009)
Category: Multidisciplinary Sciences Quartile: 1º
Impact factor: 3.730 - Sagredo O, González S, Aroyo I, Pazos MR, Benito C, Lastres-Becker I, Romero JP, Tolón RM, Mechoulam R, Brouillet E, Romero J, Fernández-Ruiz J. Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: Relevance for Huntington's disease. Glia 57, 1154-1167 (2009)
Category: Neurosciences Quartile: 1º
Impact factor: 5.066 - Palazuelos J, Aguado T, Pazos MR, Julien B, Carrasco C, Resel E, Sagredo O, Benito C, Romero J, Azcoitia I, Fernández-Ruiz J, Guzmán M, Galve-Roperh I. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington’s disease excitotoxicity. Brain 132, 3152-3164 (2009).
Category: Neurosciences Quartile: 1º
Impact factor: 9.915 - Orgado JM, Fernández-Ruiz J, Romero J. The endocannabinoid system in neuropathological states. International Review of Psychiatry 21, 172-180 (2009).
Category: Psychiatry Quartile: 2º
Impact factor: 1.798
Top
- General information
- Members
- Research lines
- Projects & contracts
- Scientific publications
- Thesis & masters
- Books
- Awards
- Equipment & facilities
- Patents
News of the cluster
- Advances in models for early prediction of crises in chronic diseases
- International Mentor Program (IMP) USA-Europe
- First direct evidence for ultra-fast responses in human amygdala to fear
- Open call MIT-Spain - CEI Moncloa Seed Fund
- Videogames against malaria: learn through playing A Malaria "Candy Crush" to research new diagnostic tools involving citizen participation.